Venetoclax and Blinatumomab for adult patients with relapsed/refractory or MRD positive Ph-negative B-cell precursor ALL: phase I part of the GMALL-BLIVEN trial.
Saved in:
| Title: | Venetoclax and Blinatumomab for adult patients with relapsed/refractory or MRD positive Ph-negative B-cell precursor ALL: phase I part of the GMALL-BLIVEN trial. |
|---|---|
| Authors: | Fransecky L; Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. lars.fransecky@uksh.de.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany. lars.fransecky@uksh.de., Fiedler W; Department of Oncology and Hematology with Section Pneumology, University Medical Center Hamburg-Eppendorf, University Cancer Center Hamburg, Hamburg, Germany., Röllig C; Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany., Sauer T; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany., Raffel S; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany., Alsdorf W; Department of Oncology and Hematology with Section Pneumology, University Medical Center Hamburg-Eppendorf, University Cancer Center Hamburg, Hamburg, Germany., Heberling L; Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany., Steer B; Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany., Huber K; Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany.; Clinical Research Unit 'CATCH ALL' (KFO 5010) funded by the Deutsche Forschungsgemeinschaft, Bonn, Germany., Versteegen T; Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany., Spory L; Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany., Deckbar D; Department of Internal Medicine II, Hematology and Oncology, Goethe University Hospital Frankfurt, Frankfurt, Germany., Reiser L; Department of Internal Medicine II, Hematology and Oncology, Goethe University Hospital Frankfurt, Frankfurt, Germany., Bendig S; Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany.; Clinical Research Unit 'CATCH ALL' (KFO 5010) funded by the Deutsche Forschungsgemeinschaft, Bonn, Germany., Bastian L; Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany.; Clinical Research Unit 'CATCH ALL' (KFO 5010) funded by the Deutsche Forschungsgemeinschaft, Bonn, Germany., Bozzetti C; Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany., Beder T; Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany., Neumann M; Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany.; Clinical Research Unit 'CATCH ALL' (KFO 5010) funded by the Deutsche Forschungsgemeinschaft, Bonn, Germany., Brüggemann M; Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany.; Clinical Research Unit 'CATCH ALL' (KFO 5010) funded by the Deutsche Forschungsgemeinschaft, Bonn, Germany., Gökbuget N; Department of Internal Medicine II, Hematology and Oncology, Goethe University Hospital Frankfurt, Frankfurt, Germany., Baldus C; Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany.; Clinical Research Unit 'CATCH ALL' (KFO 5010) funded by the Deutsche Forschungsgemeinschaft, Bonn, Germany. |
| Source: | Annals of hematology [Ann Hematol] 2026 Feb 12; Vol. 105 (3), pp. 109. Date of Electronic Publication: 2026 Feb 12. |
| Publication Type: | Journal Article; Clinical Trial, Phase I; Multicenter Study |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0584 (Electronic) Linking ISSN: 09395555 NLM ISO Abbreviation: Ann Hematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41673326 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Venetoclax and Blinatumomab for adult patients with relapsed/refractory or MRD positive Ph-negative B-cell precursor ALL: phase I part of the GMALL-BLIVEN trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Fransecky+L%22">Fransecky L</searchLink>; Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. lars.fransecky@uksh.de.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany. lars.fransecky@uksh.de.<br /><searchLink fieldCode="AU" term="%22Fiedler+W%22">Fiedler W</searchLink>; Department of Oncology and Hematology with Section Pneumology, University Medical Center Hamburg-Eppendorf, University Cancer Center Hamburg, Hamburg, Germany.<br /><searchLink fieldCode="AU" term="%22Röllig+C%22">Röllig C</searchLink>; Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany.<br /><searchLink fieldCode="AU" term="%22Sauer+T%22">Sauer T</searchLink>; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Raffel+S%22">Raffel S</searchLink>; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Alsdorf+W%22">Alsdorf W</searchLink>; Department of Oncology and Hematology with Section Pneumology, University Medical Center Hamburg-Eppendorf, University Cancer Center Hamburg, Hamburg, Germany.<br /><searchLink fieldCode="AU" term="%22Heberling+L%22">Heberling L</searchLink>; Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany.<br /><searchLink fieldCode="AU" term="%22Steer+B%22">Steer B</searchLink>; Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany.<br /><searchLink fieldCode="AU" term="%22Huber+K%22">Huber K</searchLink>; Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany.; Clinical Research Unit 'CATCH ALL' (KFO 5010) funded by the Deutsche Forschungsgemeinschaft, Bonn, Germany.<br /><searchLink fieldCode="AU" term="%22Versteegen+T%22">Versteegen T</searchLink>; Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany.<br /><searchLink fieldCode="AU" term="%22Spory+L%22">Spory L</searchLink>; Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany.<br /><searchLink fieldCode="AU" term="%22Deckbar+D%22">Deckbar D</searchLink>; Department of Internal Medicine II, Hematology and Oncology, Goethe University Hospital Frankfurt, Frankfurt, Germany.<br /><searchLink fieldCode="AU" term="%22Reiser+L%22">Reiser L</searchLink>; Department of Internal Medicine II, Hematology and Oncology, Goethe University Hospital Frankfurt, Frankfurt, Germany.<br /><searchLink fieldCode="AU" term="%22Bendig+S%22">Bendig S</searchLink>; Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany.; Clinical Research Unit 'CATCH ALL' (KFO 5010) funded by the Deutsche Forschungsgemeinschaft, Bonn, Germany.<br /><searchLink fieldCode="AU" term="%22Bastian+L%22">Bastian L</searchLink>; Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany.; Clinical Research Unit 'CATCH ALL' (KFO 5010) funded by the Deutsche Forschungsgemeinschaft, Bonn, Germany.<br /><searchLink fieldCode="AU" term="%22Bozzetti+C%22">Bozzetti C</searchLink>; Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany.<br /><searchLink fieldCode="AU" term="%22Beder+T%22">Beder T</searchLink>; Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany.<br /><searchLink fieldCode="AU" term="%22Neumann+M%22">Neumann M</searchLink>; Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany.; Clinical Research Unit 'CATCH ALL' (KFO 5010) funded by the Deutsche Forschungsgemeinschaft, Bonn, Germany.<br /><searchLink fieldCode="AU" term="%22Brüggemann+M%22">Brüggemann M</searchLink>; Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany.; Clinical Research Unit 'CATCH ALL' (KFO 5010) funded by the Deutsche Forschungsgemeinschaft, Bonn, Germany.<br /><searchLink fieldCode="AU" term="%22Gökbuget+N%22">Gökbuget N</searchLink>; Department of Internal Medicine II, Hematology and Oncology, Goethe University Hospital Frankfurt, Frankfurt, Germany.<br /><searchLink fieldCode="AU" term="%22Baldus+C%22">Baldus C</searchLink>; Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany.; Clinical Research Unit 'CATCH ALL' (KFO 5010) funded by the Deutsche Forschungsgemeinschaft, Bonn, Germany. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229107334%22">Annals of hematology</searchLink> [Ann Hematol] 2026 Feb 12; Vol. 105 (3), pp. 109. <i>Date of Electronic Publication: </i>2026 Feb 12. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Clinical Trial, Phase I; Multicenter Study – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+Verlag%22">Springer Verlag </searchLink><i>Country of Publication: </i>Germany <i>NLM ID: </i>9107334 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1432-0584 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209395555%22">09395555 </searchLink><i>NLM ISO Abbreviation: </i>Ann Hematol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41673326 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s00277-026-06883-8 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 109 Titles: – TitleFull: Venetoclax and Blinatumomab for adult patients with relapsed/refractory or MRD positive Ph-negative B-cell precursor ALL: phase I part of the GMALL-BLIVEN trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Fransecky L – PersonEntity: Name: NameFull: Fiedler W – PersonEntity: Name: NameFull: Röllig C – PersonEntity: Name: NameFull: Sauer T – PersonEntity: Name: NameFull: Raffel S – PersonEntity: Name: NameFull: Alsdorf W – PersonEntity: Name: NameFull: Heberling L – PersonEntity: Name: NameFull: Steer B – PersonEntity: Name: NameFull: Huber K – PersonEntity: Name: NameFull: Versteegen T – PersonEntity: Name: NameFull: Spory L – PersonEntity: Name: NameFull: Deckbar D – PersonEntity: Name: NameFull: Reiser L – PersonEntity: Name: NameFull: Bendig S – PersonEntity: Name: NameFull: Bastian L – PersonEntity: Name: NameFull: Bozzetti C – PersonEntity: Name: NameFull: Beder T – PersonEntity: Name: NameFull: Neumann M – PersonEntity: Name: NameFull: Brüggemann M – PersonEntity: Name: NameFull: Gökbuget N – PersonEntity: Name: NameFull: Baldus C IsPartOfRelationships: – BibEntity: Dates: – D: 12 M: 02 Text: 2026 Feb 12 Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 1432-0584 Numbering: – Type: volume Value: 105 – Type: issue Value: 3 Titles: – TitleFull: Annals of hematology Type: main |
| ResultId | 1 |
